Halozyme Therapeutics, Inc. (HALO): Are Hedge Funds Right About This Stock?
To the average investor, there are a multitude of metrics market participants can use to track stocks. A pair of the most useful are hedge fund and insider trading movement.
Merrimack Pharmaceuticals Inc (MACK)
Market is closed
News
- First
- << Previous
- 31 - 37
Should You Avoid ACADIA Pharmaceuticals Inc. (ACAD)?
To most traders, hedge funds are seen as unimportant, outdated investment tools of the past.
Should You Avoid Merrimack Pharmaceuticals Inc (MACK)?
To the average investor, there are a multitude of gauges investors can use to monitor their holdings. Some of the most under-the-radar are hedge fund and insider trading activity.
ACADIA Pharmaceuticals Inc. (ACAD): Insiders Are Dumping, Should You?
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was in 12 hedge funds' portfolio at the end of the fourth quarter of 2012.
Should You Avoid EXACT Sciences Corporation (NASDAQ:EXAS)? - Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Array Biopharma Inc (NASDAQ:ARRY)
If you'd ask most traders, hedge funds are perceived as worthless, old financial vehicles of the past.
Merrimack Pharmaceuticals Inc (MACK) May Be Right For Your Portfolio
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) may be the perfect biotech company for your speculative portfolio.
3 Events Biotech Investors Need to Watch in 2013: Vical Incorporated (VICL) and More
It's make-or-break time in 2013. That's the situation for several biotech companies with critical phase 3 trials under way.
- First
- << Previous
- 31 - 37
Billionaire Hedge Funds
